GSK plc Stock News Today (Dec. 13, 2025): EU and FDA Decisions Put Pipeline Momentum Back in Focus
Europe’s EMA has recommended approval of GSK’s depemokimab for severe asthma and chronic rhinosinusitis, with a European Commission decision expected in early 2026. GSK’s U.S.-listed ADR closed near $48.81, close to its 52-week high, as traders watched for a potential FDA decision on the drug this month.